Investigational drug for pulmonary hypertension due to heart failure

Trial ID:
IRB-23-8259
Thomas Heywood, M.D.

Inclusion Criteria

Patients must:

  • Be an adult 18 to 85 years old
    Have a clinical diagnosis of HFpEF with demonstrated Cpc-PH (WHO Group 2 PH)
    Have NYHA FC II or III
    Be on stable doses of chronic medication for HF or for any underlying condition for at least 30 days prior to Visit 1

Exclusion Criteria

Patients must not:

  • Have clinically significant and active lung disease.
    Have a known history of chronic liver disease.
    Have a body mass index of = 50 kg/m2.
    Have had prior heart-lung transplants or a life expectancy of less than 12 months.

Additional Info

Sotatercept is being studied to see if it can safely help slow the progression of PH when taken with current PH therapy.

The study treatment (either sotatercept or placebo) is given as a subcutaneous injection, a shot into the skin. The injection can be given into the upper arm, stomach, or outer thigh.

You will receive one injection every 21 days (3 weeks). You will also continue taking your current PH medication

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org